These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1620 related articles for article (PubMed ID: 33516645)

  • 21. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
    Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
    Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
    Qi Y; Yan X; Wang C; Cao H; Liu G
    Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
    [No Abstract]   [Full Text] [Related]  

  • 23. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
    Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
    Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
    Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
    Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
    Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
    World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Ferro M; Crocetto F; Tataru S; Barone B; Dolce P; Lucarelli G; Sonpavde G; Musi G; Antonelli A; Veccia A; Terracciano D; Busetto GM; Del Giudice F; Marchioni M; Schips L; Porpiglia F; Fiori C; Carrieri G; Lasorsa F; Verde A; Scafuri L; Buonerba C; Di Lorenzo G
    Clin Genitourin Cancer; 2023 Oct; 21(5):574-583. PubMed ID: 37419854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
    Nishiyama H; Tsuzuki T; Ohyama C; Matsuyama H; Shinozaki K; Hayashi Y; Hayashi N; Koto R; Shin E; Ogawa O
    Int J Clin Oncol; 2023 Oct; 28(10):1398-1410. PubMed ID: 37498492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
    Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
    Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.
    Li JB; Lai MY; Lin ZC; Guan WL; Sun YT; Yang J; Wang WX; Yang ZR; Qiu MZ
    Cancer Immunol Immunother; 2024 May; 73(7):132. PubMed ID: 38753055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
    Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D; Tang L; Hu J; Cao X; He Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
    Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
    Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
    He M; Zheng T; Zhang X; Peng Y; Jiang X; Huang Y; Tan B; Yang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1345-1355. PubMed ID: 34657171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.